Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Rare Bleeding Disorders Dr Joseph MAKDESSI TYR 31-07-2010 • Clotting factor deficiencies (I, II, V, combined V & VIII, VII, X, XI, XIII) • Platelet function disorders (e.g. Glanzmann Thrombasthenia, Bernard-Soulier Syndrome) • Increase in identified number of people with rare clotting factor deficiencies or platelet function disorders (WFH) GPIb-IX-V Complex • In 1948 Bernard & Soulier described a young man with a severe bleeding disorder, prolonged BT, thrombocytopenia and large platelets • BSS platelets fail to aggregate with ristocetin or adhere to blood vessel subendothelium • BSS platelets fail to express major membraneassociated glycoproteins: GPIbα, GPIbβ, IX and V • GPIb-IX-V complex is the receptor for Von Willebrand factor plus other adhesive proteins , and receptors, and thrombin Why the clinical effect • Macrothrombocytopenia: Megakaryocyte defects in the formation of demarcation membranes and proplatelet formation • Clinical bleeding: failure of platelets to adhere to VWF ligands in damaged vessel wall subendothelium Syndromes associated with GPIb-IX-V Bernard-Soulier syndrome: – Autosomal recessive – Macrothrombocytopenia – Deficient aggregation with ristocetin – Normal vWF multimeric pattern in plasma – Loss-of-function mutations Syndromes associated with GPIb-IX-V Platelet- type vWD – Autosomal dominant – Thrombocytopenia – Enhanced aggregation with ristocetin – Loss of HMW vWF multimers from plasma – Gain-of-function mutations Dense Granule deficiency • Mild to moderate mucocutaneous bleeding • Non syndromic • Associated with pigment abnormalities: – Hermansky-Pudlak syndrome – Chediak-Higashi syndrome – Griscelli syndrome • Associated with other inherited disorder – familial myeloid leukemia • Combined α,δ-granule deficiency • Acquired deficiencies Hermansky – Pudlak syndrome • Autosomal recessive • Presentation: – – – – δ-granule deficiency Oculocutaneous albinism Pulmonary fibrosis Granulomatous colitis • Defects in three cytoplasmic organelles: – Platelet dense granules – Melanosomes – lysosomes MYH9-Related Disorders • Autosomal dominant disorders of macothrombocytopenia, platelet dysfunction, and leuKocyte inclusions – – – – May-Hegglin Anomaly Sebastian syndrome Fechtner syndrome Epstein syndrome • Clinical aspects: – – – – Mild bleeding diathesis Renal disease Hearing loss cataracts Why The Clinical Effects • Macrothrombocytopenia: disordered cytoskeleton affecting proplatelet formation • Platelet dysfunction: abnormal cytoskeletal reorganization and shape change • Other organ dysfunction may be related to defects in: – – – – Epithelial cell organization Cell-matrix adhesion Cell migration and differentiation Tissue morphogenesis Inherited Platelet Disorders • Study of these rare platelet disorders: – Has identified specific molecular defects – Reveals the physiology of the normal • Understanding the basic mechanisms: – May explain unusual syndromic associations – Improves our understanding of more common diseases – May help to identify new therapeutic targets Glanzmann Thrombasthenia (GT) • It was first described by Glanzmann in 1918 as hereditary hemorrhagic thrombasthenia • It is an autosomal, recessive, bleeding syndrome affecting megakaryocyte lineage • It is characterized by lack of platelet aggregation • It is moderate to severe disorder with mainly mucocutaneous bleeding Cell Biology • In GT, platelets fail to aggregate in response to all natural agonists,although they undergo normal shape change • Thrombasthenic platelets can also adhere to exposed subendothelial matrix and undergo exocytosis of storage granules • The inability of the platelets to bind these adhesive proteins explains the platelet phenotype in GT Epidemiology • GT is a rare disease with an estimated prevalence of 1/million • The disease is known to have a higher prevalence in communities where consanguinity is common • Examples of these communities include: Indians, Iranians, Iraki Jews, Palestinian and Jordanian Arabs, French gypsies • GT related bleeding is more common in females, probably due to menorrhagia Inheritance • GT is an autosomal recessive bleeding disorder • Heterozygote individuals are usually asymptomatic carriers • Heterozygote couples may have a homozygote offspring who will have moderate to severe disease Hematological Work Up • CBC, Blood group, Ferritin, aPTT, PT, vWF Ag, RiCof • If abnormal : Specific Coagulation Assays • If normal: suspect platelet dysfunction Platelet Function Tests • Prolonged BT or abnormal PFA 100 closure time • Defective aggregation with ADP, thrombin, epinephrin or collagen alone or in combination • Defective clot retraction test • Deficiency of αIIbβ3 in new patients should always be demonstrated by specific monoclonal antibodies using flow cytometry Transfusion in GT • Patients with GT may have frequent transfusions throughout their lives • They may be more exposed to transfusion complications mainly: transmission of viral diseases and Bacteria. • Immunological complications: – Allergy and anaphylaxis – Platelet isoantibody formation and refractoriness • To avoid these complications the following requirements should be considered whenever possible: – Pathogen inactivated platelets – Leucoreduced cellular blood components – Reduction of plasma volume in RBCs and Platelets concentrates by the use of additive solutions – Use of HLA, HPA matched platelets, or cross matched platelets whenever platelet alloimmunization and refractoriness develop